Recent advances in the treatment of benign prostatic hyperplasia

Journal of the Formosan Medical Association

Volumn 95, Issue 11, 1996, Pages 822-827

  Lai, Ming Kuen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

apoptosis; benign prostatic hyperplasia; estrogen; growth factors; p53 gene; testosterone; transurethral resection of the prostate (TURP)

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLUTETHIMIDE; ATAMESTANE; FINASTERIDE; GROWTH FACTOR; KETOCONAZOLE; PHENOXYBENZAMINE; PLANT EXTRACT; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

HUMAN; MALE; PROSTATE HYPERTROPHY; REVIEW; TRANSURETHRAL RESECTION;

HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 0030464379     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Arrighi HM, Metter EJ, Guess HA, et al: Natural history of benign prostatic hyperplasia and risk of prostatectomy: the Baltimore longitudinal study of aging. Urology 1991;37 (suppl 1):4-8
2. Boyle P, McGinn R, Maisonneuve P, et al: Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol 1991;20 (suppl 1):3-10.
3. Chang HL, Char GY: Benign by pertrophy of the prostate. Chin Med J 1936;50:1707-22.
4. Department of Health, the Executive Yuan: Report on patient survey in hospitals and clinics. Taiwan Area, ROC 1993:133.
5. Barry MJ: Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1900;17:499-507.
6. McClure RD: Endocrine investigation and therapy. Urol Clin North Am 1987;14:471-88.
7. Wu JP, Gu FL: The prostate 41-65 years post-castration - analysis of 26 eunuchs. Chin Med J 1987;100:271-2.
8. Davies P, Eaton CL: Regulation of prostatic growth. J Entlocrinol 1991;131:5-17.
9. White JW: The results of double castration in hypertrophy of the prostate. Ann Surg 1895;22:1-80.
10. Imprato-McGinley J, Guerrero L, Gantier T, et al: Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186:1213-5.
11. Gormley GJ, Stoner R, Bruskewitz RC, et al: The effect of finasteride in men with benign prostatic hyperplasia. New Engl J Med 1992;327:1185-91.
12. Yu HJ, Chiu TY, Lai MK: Therapeutic effects, of finasteride in benign prostatic hyperplasia: a randomized double-blind control trial. J Formos Med Assoc 1995;94:37-41.
13. Barrack ER, Berry SJ: DNA synthesis in the canine prostate: effects of androgen and estrogen treatment. Prostate 1987;10:45-56.
14. Mori H, Maki M, Oishi K, et al: Increased expression of genes, for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia. Prostate 1990;16:71-80.
15. Mydlo JH, Michaeli J, Heston WDW, et al: Expression of basic fibroblast growth factor mRNA in benign prostate hyperplasia and prostate carcinoma. Prostate 1988;13:241-7.
16. Storv MT, Livingstone B, Baeten L, et al: Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 1989;15:355-65.
17. Coffey DS, Walsh PC: Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461-75.
18. Harriss DR, Savill J: Apoptosis and the prostate. Br J Urol 1995;75 (suppl 1):27-33.
19. Meyer FJ, Chi SG, Fishman JR, et al: p53 mutations in benign prostatic hyperplasia. J Nat Cancer Inst 1993;85:1856-8.
20. Kallakurv UV, Jennings TA, Ross JS, et al: Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high-grade prostatic adenocarcinoma. Diagn Molecular Pathol 1994;3:227-52.
21. Zhang X, Colombel M, Raffo A, et al: Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate gland. Biochem Biophys Res Commun 1994;198:1184-94.
22. Berges RR, Furuya Y, Remington L, et al: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 1993;90:8910-4.
23. Deitch AD, Miller GJ, de Vere White RW: Significance of abnormal diploid DNA histogram in localized prostate cancer and adjacent benign prostatic tissue. Cancer 1993;72:1672-700.
24. Boyarsky S, Tones G, Paulson DF, et al: A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1976;68:29-32.
25. Madsen PO, Iversen P: A point system for selecting operative candidates. In: Hinman F Jr, ed. Benign Prostatic Hypertrophy. New York: Springer-Verlag, 1983:763-5.
26. Barry MJ, Fowler FJ Jr, O'Leary MP, et al: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the Am Urol Assoc. J Urol 1992;148:1549-57.
27. Mebust WK: Symptom evaluation, quality of life and sexuality. In: Cockett ATK, Khoury S, Aso Y, et al, eds. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International, 1993:127-50.
28. Guh JH, Chueh SC, Ko FN, et al: Characterization of α1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. Br J Pharmacol 1995;115:142-6.
29. Kitagawa N, Ichikawa T, Akimoto S, et al: Natural course of human benign prostatic hyperplasia with relation to urinary disturbance. Prostate 1994;21:279-84.
30. Trapasso JG, Irwin MB: Clinical outcome and reoperation after low-weight transurethral resection of the prostate. J Endourol 1994;8:165-7.
31. Rosier PFWM, De La Rosette JJMCH, Koldewijn EL, et al: Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia. J Urol 1995;153:1520-5.
32. Barry MJ, Girman CJ, O'Leary MP, et al: Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. J Urol 1995;153:99-103.
33. Hedlund H, Anderson KE, Ek A: Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983;130:275-8.
34. Ferrie BG, Patterson PJ: Phenoxybenzamine in prostatic hypertrophy: a double-blind study. Br J Urol 1987;39:63-5.
35. Kawabe K, Ueno A, Takimoto Y, et al: Use of an alpha-1 blocker, YM617, in the treatment of benign prostatic hypertrophy: YM (1) Clin Study Group. J Urol 1990;144:908-11.
36. Silver RL, Wiley EL, Thigpen AE, et al: Cell type specific expression of steroid 5α-reductase 2. J Urol 1994;152: 438-42.
37. Stoner E: The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia: the Finasteride Study Group. J Urol 1992;147:1298-302.
38. Laroqne PA, Prahalada S, Gordon LK, et al: Effects of chronic oral administration of a selective 5α-reductase inhibitor, finasteride, on the dog prostate. Prostate 1994;24:93-100.
39. Stoner E: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-92.
40. The MK-906 (Finasteride) Study Group: One year experience in the treatment of benign prostatic hyperplasia with finasteride. J Androl 1991;12:372-5.
41. Habenicht UF, El Etreby MF: Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia: experimental studies. J Androl 1991;12: 395-402.
42. Schroder FH: Changing approaches in the treatment of benign prostatic hyperplasia. Eur Urol 1991;20 (suppl 1): 63-7.
43. Mebust WK, Holtgrewe HL, Cockett ATK, et al: Transurethral prostatectomy immediate and postoperative complication: a cooperative study of thirteen participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7.
44. Fuglsig S, Aagaard J, Jonler M, et al: Survival after transurethral resection of the prostate: a 10-year follow up. J Urol 1994;151:637-9.
45. Spear KA, Bollard GA, Summers JL, et al: Early discharge of transurethral prostatectomy patients with an indwelling Foley catheter. Urology 1994;43:333-6.
46. Perlmutter AP, Muschter R, Razvi HA: Electrosurgical vaporization of the prostate in the canine model. Urology 1995;46:518-23.
47. Johnson DE, Cromeens DM, Price RE: Transurethral incision of the prostate using the holmium: YAG laser. Lasers Surg Med 1992;12:364-9.
48. Bolton DM, Costello AJ: Management of benign prostatic hyperplasia by transurethral laser ablation in patients treated with warfarin anticoagulation. J Urol 1994;151:79-81.
49. Kabalin JN, Gill HS, Bite G, et al: Comparative study of laser versus electrocautery prostatic resection: 18-month following with complex urodynamic assessment. J Urol 1995;153:94-8.
50. Steg A: Transurethral versus open prostatetomy: do these procedures apply to the same patients and same disease? Eur Urol 1991;20:173-4.
51. De la Rosette JJM, De Wildt MJ, Alvizatos G, et al: Transurethral microwave thermotherapy in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994;44:58-63.
52. Montorsi F, Guazzoni G: Is there a role for transrectal microwave hyperthermia in the treatment of benign prostatic hyperplasia? A critical review of a six-year experience. J Endourol 1995;9:333-7.
53. Schulman CC, Zlotta AR, Rasor JS, et al: Transurethral needle ablation (TUNA): safety, feasibility, and coherence of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol 1993;24:415-23.
54. Nordling J, Holm HH, Klarskov P, et al: The intraprostatic spiral: a new device for insertion with the patient under local anesthesia and with ultrasonic guidance with 3 months of follow up. J Urol 1989;142:756-8.
55. Yachia D: Spontaneous breakage of self-retaining intraprostatic stent. J Urol 1990;144:997-8.
56. Bihrle R, Foster RS, Sanghvi NT, et al: High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. J Urol 1994;151:1271-5.
57. Lanigan D, Jurriaans Z, Roobottom C, et al: Ultrasound-guided cryoprostatectomy: a potential alternative to transurethral prostatic resection in the high risk patient. Min Invas Ther 1993;2:47-50.
58. Stewart SC, Benjamin D: Electrovaporization of the prostate: new technique for treatment of symptomatic benign hyperplasia. J Endourol 1995;9:413-6.
59. Lepor H: Nonoperative management of benign prostatic hyperplasia. J Urol 1989;141:1283-9.